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This task force reviews the technical status and strength of
evidence for the use of carotid ultrasonography, coronary
computed tomography (CT), cardiovascular magnetic reso-
nance imaging (CMR), brachial artery reactivity testing
(BART), and the ankle-brachial index (ABI) in the nonin-
vasive indication of the functional or anatomic manifesta-
tions of atherosclerosis. These methods are either currently
used or have potential for use in the cardiovascular risk
assessment.
The U.S. Preventive Services Task Force recommended
in its 1996 report that any screening test utilized in the
assessment of risk can be considered effective if it: 1)
provides an accurate determination of the likelihood that an
asymptomatic person has the condition (accuracy); 2) if its
results are stable when repeated (reliability); and 3) if early
intervention is likely to have a beneficial impact (1). As an
extension of these concepts, we further recommend that any
imaging method for prediction of cardiovascular risk should
have incremental value to the risk predicted by office-based
risk assessment. This Task Force examined atherosclerosis
imaging from the perspective of accuracy and reliability
of the technologies, whereas the issue of appropriate
intervention and incremental value is more fully dis-
cussed in other Task Force reports of this Bethesda Con-
ference. This Task Force urges the adoption of standard
methodology for each of the imaging methods so that data
can be shared and assessed for quality control measure-
ments. Currently, different protocols and standardization
are used by different laboratories, and it is difficult to
establish normal and abnormal (age and gender adjusted)
values. Also, prior to the widespread adoption of any
imaging technique, it is essential that it be shown to be
reproducible, have low biologic variability, and to be clini-
cally useful. In addition, the Task Force recognizes that
although the literature often refers to test outcomes as
dichotomous for purposes of analysis, the test results of all
of these techniques are actually on a continuous scale.
Consideration of actual results, adjusted for age, gender, and
race, adds valuable information to just a positive or negative
result.
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SPECTRUM OF IMAGING METHODS
Carotid ultrasonography. METHODOLOGY. Carotid ultra-
sonography has traditionally been used clinically in the
setting of symptomatic cerebrovascular disease or asymp-
tomatic carotid bruit to identify significant obstructive
disease, quantified using Doppler technology. More re-
cently, carotid ultrasonography has been used to assess
atherosclerosis in epidemiologic studies or in risk stratifica-
tion by measuring the combined intima-media thickness
(IMT) (example shown in Fig. 1) and determining the
presence or absence of focal atherosclerotic plaques (2–5).
Because the velocity of blood flow does not substantially
increase until significant obstruction (greater than 50%)
occurs, Doppler quantification of carotid disease detects
significant obstruction uncommonly in population-based or
screening studies.
Carotid IMT is most commonly measured from B-mode
(two-dimensional) images with commercially available lin-
ear ultrasound transducers typically utilizing frequencies
between 7.5 and 10 MHz. The measurement of IMT is
rapid, completely noninvasive (no ionizing radiation), and
has the advantage of focusing only upon the intended target
(the carotid artery), thus avoiding problems of incidental
scan findings. An alternative approach is to use two-
dimensionally-guided M-mode images that provide compa-
rable spatial resolution but superior temporal resolution—
for example, in the assessment of vascular function.
Electrocardiographic (ECG) gating to determine the min-
imum end-diastolic diameter is optimal with either ap-
proach because of cyclic variation in IMT diameter due to
pulsatile changes in distending pressure. The most prefera-
ble site for the measurement of IMT is the far wall rather
than the near wall of the carotid artery because acoustic
reflection of the echo-dense intima into the lumen and/or to
high gain setting in near wall measurements may lead to
overestimation of IMT. Because the common carotid artery
(CCA) is tubular and can be aligned perpendicular to the
transducer beam, reproducibility and yield of CCA IMT is
superior to that of IMT of the carotid bifurcation (bulb) or
internal carotid artery (ICA) (5,6). The small size of the
carotid IMT (usually less than 1 mm) necessitates
computer-assisted measurement using electronic calipers;
when measurements are taken from M-mode images, full-
screen display is necessary. Semiautomated measurement
may be performed of a selected segment (usually 1 cm in
length) using an edge detection algorithm (7).
Discrete plaques, commonly defined as focal thickening
at least 50% greater than the surrounding wall, can be
reliably detected and localized by thorough scanning of the
extracranial carotid arteries. However, because the over-
whelming majority of plaques are nonobstructive and can-
not be quantified using Doppler technology, precise quan-
tification of plaque burden is problematic. Although plaque
diameter (maximum excursion into the vessel lumen) is
readily measurable, the diameter may correlate poorly with
plaque size or volume given the variable and complex
three-dimensional morphology of plaques. Semiquantitative
approaches include averaging of plaque diameters, the
number of segments (CCA, bulb, ICA, external carotid
artery [ECA]) containing plaque, or plaque number.
DEFINITION OF ABNORMAL IMT. In general, greater IMT
values are associated with greater cardiovascular risk. For
example, the Kuopio Ischaemic Heart Disease Risk Factor
Study found myocardial infarction (MI) risk increased by
11% for each 0.1 mm increase in common carotid IMT (8).
Despite this continuous relationship between IMT and risk,
an absolute definition of an abnormally high IMT (mea-
sured in the absence of plaque) is problematic due to the
strong influence of age on arterial wall thickness in both
normotensive and hypertensive individuals (5,9). Further-
more, hypertension increases IMT, probably because of
medial hypertrophy, independent of typical atherosclerotic
changes (9,10). Thus, the use of an absolute threshold to
define an abnormal IMT may result in systematic underde-
tection in younger individuals and overdetection in older
individuals. An alternate approach has been to establish
nomograms or ratios of observed to predicted IMT based on
age and other potential covariates depending upon the
population and application. The approximate age-adjusted
75th percentile values for common carotid IMT are shown
in Figure 2 (5,11,12). These values establish a level of
age-adjusted relative risk, and may be appropriate thresh-
olds indicating the need for increased attention to cardio-
vascular risk factors and risk-reduction therapies.
REPRODUCIBILITY AND VARIABILITY. Because of the ease
of performance, low risk (no ionizing radiation), and rela-
tively high degree of reproducibility of IMT measurements,
IMT has been a common surrogate end point epidemiologic
studies (2–5) and in clinical trials (13–15) to assess the
effects of various interventions on atherosclerosis burden.
These trials demonstrate the potential utility of serial
measurements of IMT in individuals. The Cholesterol
Lowering Atherosclerosis Study established that both the
absolute value and rate of progression of IMT are markers
Figure 1. An example of an ultrasound image from the distal common
carotid artery with quantification of intima-media thickness. CIMT 
carotid intima-media thickness.
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of adverse cardiovascular outcomes among groups of pa-
tients (16). Such assessments in individual patients will be
highly dependent on the reproducibility of IMT measure-
ments from any particular laboratory. Reproducibility stud-
ies have indicated that absolute intrareader differences in
common carotid IMT are in the range of 0.04 mm;
however, these differences may be somewhat reduced by the
use of more modern imaging equipment (operating at a
higher imaging frequency), digital image acquisition and
analysis, and the use of automated edge detection devices for
quantitation (7). Because even small changes in IMT can
alter cardiovascular risk predictions, the accuracy of serial
IMT assessments would be enhanced by either a greater
interval between scans or multiple assessments across time
showing consistent results.
Coronary CT imaging. METHODOLOGY. Radiographic
techniques can detect arterial calcium deposits in any
vascular bed. For example, calcified plaques in the thoracic
aorta are detectable with the simple chest radiograph, and
these were associated with increased cardiovascular risk in
the Framingham Heart Study (17). Likewise, coronary CT
scans can detect and quantitate the presence of coronary
artery calcium deposits with ECG-gated images obtained
with either electron-beam computed tomography (EBCT)
(example shown in Fig. 3) or helical CT scanners. The
EBCT uses an electron sweep of stationary tungsten target
rings to generate X-ray images that can detect small
amounts of calcium with considerable accuracy, whereas
helical CT uses a continuously rotating X-ray source. The
EBCT is accomplished by a sequence of subsecond (50 to
100 ms) 3- or 6-mm slices performed during a breathhold
sequence of approximately 40 s (dependent on heart rate).
In comparison, helical CT scanners have somewhat slower
scan times (100 to 200 ms). The entire test takes less than
15 min to complete, and it exposes the patient to a moderate
amount of ionizing radiation (less than 200 milliRem
[mrem], or approximately 10 to 15 standard chest radio-
graphs) (18).
Both coronary CT methods are highly sensitive and
accurate for the detection of coronary calcium based upon
comparisons with autopsy samples (19–21). Coronary cal-
cium is most commonly quantitated using a combination of
the area and density of calcified atherosclerosis within
Figure 2. Approximate age and gender values for common carotid intima-media thickness (CIMT) representing the approximate 75th percentile value
(4,12). Note that intima-media thickness increases with advancing age, and that the intima-media thickness of men is generally greater than that seen in
women.
Figure 3. An example of an abnormal EBCT scan taken from a 59-year-
old man. The coronary calcium score was 1,101, greater than the 90th
percentile value for age and gender. Arrow indicates calcified atheroscle-
rosis in the proximal left coronary artery.
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regions that exceed a radiographic density of 130
Hounsfield (H) units (22). An EBCT scanner costs approx-
imately $1.5 million and is currently available from only one
manufacturer (Imatron). The competing technology, helical
CT, requires a helical scanner, which costs $1.5 million to
$3 million. The helical scanner also has the advantage that
it can be used for other types of CT scanning. In any type
of coronary CT, other structures in the upper abdomen and
thorax are present in the field of view, and thus incidental
scan findings may be encountered. The frequency of inci-
dental findings can be as high as 50% in more elderly or
referred populations with comorbid conditions (23).
DEFINITION OF AN ABNORMAL CALCIUM SCORE
The presence of any single focus of calcium (generally
defined as a radiographic lesion consisting of at least four
contiguous calcified pixels on a CT scan with a given field of
view) is considered abnormal, but the prevalence of any
detectable calcium becomes very common with aging. For
men, the likelihood of having any detectable coronary
calcium is roughly equivalent to their age; for women, the
probability is 10 to 15 points below their age. In terms of the
extent of coronary calcium present, the definition of an
abnormal scan varies widely in the published reports. Sim-
ilar to the prevalence of coronary calcium, the extent of
calcium increases with age, and women again lag about 10
years behind men (24,25). Considering age and gender-
adjusted relative risk for the development of coronary heart
disease, thresholds of risk range from scores above the
median to scores above the 90th percentile. In general,
higher scores have been equated to higher cardiovascular
risk (Fig. 4). A meta-analysis of the published data found
that a calcium score above the population median value was
associated with an unadjusted odds ratio of 4.2 (95%
confidence interval [CI] 1.6 to 11.3) for an MI or death
(26). These data have been limited by selection bias within
the populations studied, and individual investigations have
found widely varying point estimates of risk. An alternative
is to establish absolute risk thresholds, although the recom-
mended cut points have varied very widely in the published
data from 80 to 640. It remains controversial whether the
coronary calcium score will add incremental information
over the standard risk-factor assessment (27–29).
Reproducibility and variability. There is much variability
noted in the relationship between coronary calcium and
atherosclerosis (30) and in the individual relationship be-
tween angiographic disease and coronary calcium quantity
(30). Studies show significant retest variability in calcium
scores obtained from repeated scans. In one study of scans
on the same patient on two consecutive days, read by a
single experienced reader, variability was 49%  45% (31).
The investigators caution that use of calcium for screening
purposes should report a range of score results to minimize
this problem with interpretation.
In another study of interobserver variability, disagreement
on calcium scores occurred in 24% of cases by two experi-
enced observers. Potential sources of error include the
partial volume effect, respiratory artifact, and errors in
calcium measurements. Various solutions have been pro-
posed, such as changing the ECG triggering method (6),
volumetric scoring systems (32), averaging results from two
or more consecutive scans, using techniques to minimize
respiratory motion artifact, and possibly the use of greater
CT slice thickness (33). Using such techniques and with
current generation CT hardware, variability can be substan-
tially reduced, and test-retest variability of 10% or less is
achievable (34). Although the prognostic significance of
coronary calcium progression is unknown, serial calcium
scores using a three-dimensional (3D) reconstruction tech-
nique have been utilized as a surrogate end point of a
prospective study evaluating the effects of lipid-lowering
therapies (35). The correlation to clinical end points has not
yet been tested. The application of serial scanning is not
known, but will be of limited value in individuals with low
calcium scores in whom small absolute changes in the
calcium score are more likely to be due to interscan
variability.
CMR. METHODOLOGY. High-resolution CMR has po-
tential as an in vivo modality for atherosclerotic plaque
imaging and characterization. The CMR differentiates
plaque components (e.g., fibrous cap, calcium, necrotic core)
on the basis of biophysical and biochemical parameters such
as chemical composition and concentration, water content,
physical state, molecular motion, or diffusion (36,37).
In vivo CMR images of advanced lesions in carotid
arteries have been obtained from patients referred for
endarterectomy (38–40). The carotid arteries’ superficial
location and relative absence of motion present less of a
technical challenge for imaging than the aorta or coronary
arteries. Short T2 components were quantified in vivo
before surgery and correlated with values obtained in vitro
after surgery (39). Thoracic aortic plaque was assessed with
multicontrast CMR and compared to transesophageal echo-
cardiography (TEE) (example shown in Fig. 5) and showed
good correlation for plaque composition and mean maxi-
mum plaque thickness (41). Although coronary atheroscle-
rosis measurements are currently limited by the spatial and
temporal constraints of CMR, CMR represents an area of
active investigation (42,43).
In theory, the capability of CMR to identify not only the
extent but also the characteristics of atherosclerotic plaque is
a potential advantage of CMR techniques. Further im-
provements in external coils, imaging acquisition, and the
use of contrast agents that enhance the different vessel wall
components may improve in vivo noninvasive CMR char-
acterization of the plaque. Beyond feasibility, the hierarchy
of anatomic targets relative to cardiovascular prognosis for
CMR atherosclerosis imaging has not yet been defined.
Definition of an abnormal CMR. Cardiovascular mag-
netic resonance imaging including multi-contrast CMR
(T1-, T2-, proton density-weighted and time-of-flight) has
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Figure 4. All-cause survival in 4,474 men and 3,219 women with greater than one cardiac risk factor by EBT coronary calcium measurements: Results from a stratified Cox proportional hazards survival model

















been shown to accurately image and characterize carotid
arterial plaques in vivo (44). Specific capabilities include the
quantification of plaque size (45–47), the detection of
fibrous cap “integrity” (48), lipid core, and acute intraplaque
hemorrhage (49). Data on the extent of aortic thickness
within screening populations are beginning to emerge. A
cross-sectional study (50) from the Framingham Heart
Study offspring cohort found that plaques identified by
CMR are two to three times more prevalent in the abdom-
inal than the thoracic aorta. Comparable to quantitative
atherosclerosis burden measurements with coronary CT and
carotid IMT, the extent of plaque progressively increased
with increasing patient age, approximately doubling for each
decade. The optimal vascular bed and method for quanti-
fying reported CMR-determined atherosclerosis extent re-
mains to be established in future prospective clinical trials.
Further, the prognostic significance of quantitative (e.g.,
plaque thickness) versus qualitative (e.g., presence of a
“thin” fibrous cap) atherosclerosis measures has not been
established.
Reproducibility and variability. In one of the lipid-
lowering CMR studies of human aortic and carotid plaques
(46), the reproducibility of the vessel wall area measurement
was assessed after repeated imaging. The error in vessel wall
area measurement was found to be 2.6% for aortic and 3.5%
for carotid plaques. Similar low measurement errors in
plaque area and volume (4% to 6%, respectively) were
reported by others, proving that plaque area and volume can
be accurately assessed (51,52). Based upon these favorable
retest characteristics, CMR has been successfully used as an
intermediate end point in interventional trials of antiath-
erosclerosis treatments. For example, in a study of lipid-
lowering therapy (statins) in asymptomatic untreated hyper-
cholesterolemic patients with carotid and aortic
atherosclerosis (46,53), regression of atherosclerotic lesions
was observed in the aortic and carotid arteries vessel wall at
12 months. These capabilities may extend to serial testing of
plaque components with CMR. Patients with coronary
artery disease (CAD) who received lipid-lowering therapy
(niacin, lovastatin, and colestipol) for 10 years in the
Familial Atherosclerosis Treatment Study (FATS) group
were shown to have decreased lipid composition (estimated
as a fraction of total plaque area) and an increased fibrous
tissue composition in the treated group compared to the
untreated group.
Brachial artery reactivity testing. METHODOLOGY. Endo-
thelial cells produce nitric oxide, which is the predominant
vasodilator in the arterial system. An increase in shear stress
on the surface of endothelial cells initiates a signaling
pathway that results in phosphorylation and activation of
nitric oxide synthase, resulting in an increase in bioavailable
nitric oxide (54). Inhibition of nitric oxide synthase reduces,
but does not eliminate, vasodilation, suggesting that other
vasodilators are also involved. Endothelial-derived nitric
oxide inhibits many of the initiating steps in the pathogen-
esis of CAD, including low-density lipoprotein (LDL)
uptake, white cell adhesion to the vessel wall, vascular
smooth muscle proliferation, and platelet adhesion and
aggregation (55). The degree of arterial vasodilation in the
face of a flow-mediated increase in shear stress serves as a
Figure 5. Transesophageal CMR images from two poststroke patients with increased LDL-cholesterol showing (A) homogeneous (from a 56-year-old
African American hypertensive woman) and (B) heterogeneous (from a 72-year-old Caucasian man) CMR signal from thickened aortic walls. The scales
are different (in actuality, the aortae have similar diameters), but the nonuniformity of wall thickness and heterogeneous signal, suggesting lipid infiltration
from the patient portrayed in B, is clearly seen. In addition, these studies revealed the pitfalls of transesophageal echocardiography to assess aortic
atherosclerosis caused by its near-field limitations in imaging the anterior aspect of the aortic wall.
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bioassay of endothelial cell capacity to produce and release
nitric oxide, and thus, is an indirect indicator of endothelial
function. Furthermore, clinical studies show that endothe-
lial dysfunction can become evident well in advance of the
development of clinical or anatomic manifestations of ath-
erosclerosis (56,57). For these reasons, impaired flow-
mediated vasodilator responses may represent one of the
earliest stages of the development of vascular disease. Thus,
this technique could be most useful to screen for early stages
of arterial disease, especially in children and young adults
(58), at a time when risk factor and other interventions
might be more effective.
Subject preparation is important, because several factors
can affect flow-mediated vascular responses (e.g., smoking,
fat or caffeine ingestion, drugs, temperature, sympathetic
stimuli) (59–61). Subjects should not smoke or eat for 8 to
12 h before the study, and a quiet, temperature-controlled
room should be used for the procedure. In premenopausal
subjects, investigators should determine the phase of the
subject’s menstrual cycle, which can influence flow-
mediated dilation (62).
The equipment required to measure brachial artery flow-
mediated responses includes a computer equipped with
software to measure changes in brachial diameter and a high
frequency ultrasound instrument with a vascular transducer
and built-in ECG capabilities. The preferred transducer for
optimal image resolution is a broad-band linear array model
(7 to 12 MHz frequency range). After the subject has rested,
the procedure is begun by placing a sphygmomanometric
cuff on the forearm or above the antecubital fossa. Baseline
ultrasound images are acquired by the sonographer. Then
the cuff is inflated (typically to 50 mm Hg above the
subject’s resting systolic blood pressure) for a standardized
period (typically 5 min) to create ischemia and reactive
hyperemia in the downstream resistance arteries. Following
cuff release, this distal hyperemia produces a transient
increase in blood flow through the conduit brachial artery
(about six-fold increase). The sonographer acquires addi-
tional images following cuff release to document the degree
of vasodilation. Most commonly, vasodilation is measured 1
min after cuff release; however, some systems have the
capacity to continuously monitor changes in brachial diam-
eter during the entire 1- to 2-min dilation phase. In most
studies, subjects are then given a single dose of nitroglycerin
(spray or sublingual, 0.4 mg) to assess endothelium-
independent vasodilation and thus vascular smooth muscle
function.
High-quality ultrasound images are essential for accurate
analyses of brachial artery flow-mediated response. Clear
visualization of both the near and far wall lumen-intima
boundaries is required before the study begins. Boundaries
for measurement (either the lumen-intima or media-
adventitia interfaces) can be identified with edge calipers by
the operator or edge-detection software packages. The
response is generally measured as change in poststimulus
diameter, as a percentage of the baseline diameter.
Definition of an abnormal brachial artery response. The
normal range of vasodilator responses varies, depending on
the placement of the blood pressure cuff. In general, in
normal individuals, cuff placement on the distal forearm
produces vasodilator responses greater than 5%, whereas
placement of the cuff above the antecubital fossa results in
vasodilator responses greater than 8%. However, many
things influence these vasodilator responses. In particular,
age is a potent attenuator of vasodilator responses (especially
above 40 and 50 years in men and women, respectively)
(63,64). Vasodilation is also strongly inversely dependent on
baseline arterial diameter (63). Small studies have shown
that reduced brachial artery flow-mediated vasodilation is
associated with a greater likelihood of CAD and poorer
prognosis in individuals with chest pain (approximately
three-fold relative risk) (16,47).
Reproducibility and variability. The major limitation to
BART is the inherent biologic variability in the measure-
ment. The vasodilator response to forearm ischemia varies
greatly within an individual in response to many different
variables. For example, changes in dietary patterns (a high-
fat meal) and the phase of a woman’s menstrual cycle each
can alter the results of BART.
Ankle-brachial index. METHODOLOGY. The ankle-
brachial index (ABI) is the ratio of the systolic blood
pressure (SBP) at the ankle divided by the SBP in the arm.
The underlying principle is that when a stenosis in a
peripheral artery reaches a critical level, a decrease occurs in
effective perfusion pressure distal to the stenosis, and this
decrease is roughly proportional to the severity of the
occlusive disease.
The test is painless, simple to perform, and quite inex-
pensive. Vascular laboratories often measure limb SBP at
multiple levels of the lower extremity (e.g., thigh, above
knee, below knee, ankle, and toe), which can help localize
any peripheral arterial disease (PAD) present. However, the
researcher or clinician screening for PAD typically measures
only the ankle pressure, because this will detect proximal as
well as distal disease. In addition, the width of the standard
arm cuff (12 cm) is particularly compatible with the usual
girth at the ankle. A cuff size appropriate for arm size is used
for the brachial SBP, and a 12-cm cuff is used at the ankle
in all but rare instances. The brachial SBP is taken in both
arms using a hand-held Doppler at the brachial artery in the
antecubital fossa, and the higher of the two arm pressures is
used as the denominator for the ABI calculation for each
leg. The higher arm pressure is used to avoid a falsely low
arm pressure from subclavian stenosis, which is more
common in patients with PAD. At each ankle (right and
left), the SBP is measured in both the posterior tibial and
dorsalis pedis arteries, using the handheld Doppler. The
higher of the two pressures at the right ankle is the
numerator for the right ABI, and the higher of the two
pressures at the left ankle is the numerator for the left ABI.
Definition of an abnormal ABI. In contrast to cardiovas-
cular imaging methods, the ABI is not an imaging tech-
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nique and does not detect early plaque formation or minimal
stenosis. The ABI generally is a test that detects individuals
with more advanced (although often asymptomatic) vascular
disease. An abnormal ABI, defined as a value less than or
equal to 0.90, has a sensitivity of about 90% and a specificity
of about 98% for moderate or greater obstructive PAD on
angiography (65,66). The use of the ABI is particularly
important giving the limited sensitivity, specificity, and
predictive value of the traditional clinical assessments for
PAD (pulse palpation and symptom assessment) (67). The
ABI can detect subclinical (asymptomatic) cardiovascular
disease (CVD), and up to 40% of patients with abnormal
ABI tests have no symptoms (67,68). Some subjects with
complaints of claudication may show a normal ABI at rest,
but exercise will often uncover a low ABI. A simple pedal
plantar flexion test may be substituted for a treadmill in
office practice (69).
Reproducibility and variability. The variability in SBP in
both the ankle and arm is similar, and the ABI shows fair
repeatability, with a 95% CI of 16% for a single measure-
ment, which improves to10 % when taken as the mean of
four measurements (70). Based upon these test-retest char-
acteristics, the ABI is generally poorly suited to serial
testing, and thus it is more commonly used in cross-
sectional population screening.
EMERGING TECHNOLOGIES:
NUCLEAR IMAGING OF VULNERABLE PLAQUE
Several novel and emerging technologies are being devel-
oped to evaluate subclinical atherosclerosis, including vari-
ous radiolabeled monoclonal antibodies targeting molecular
components of atherosclerosis. Animal studies have dem-
onstrated the feasibility of in vivo nuclear imaging of
atherosclerotic plaques using radiolabeled antibodies tar-
geted to oxidized LDL and to components (such as apo-
ptotic cells) of necrotic core. Serial studies in animals have
also been performed showing the ability to track the
oxidized LDL content in plaque after hypolipidemic treat-
ments. Alternatively, increased inflammation within symp-
tomatic atherosclerosis can be imaged using 19
F-fluorodeoxyglucose, as has been recently demonstrated in
carotid atherosclerosis. Feasibility, accuracy, and clinical
utility have not yet been demonstrated for coronary lesions
or in human subjects.
Validation studies of different imaging technologies. All
tests require formal technology assessments so as to be
considered a valid clinical tool. Such initial technical eval-
uations are typically performed using cross-sectional study
designs relative to a reference standard. For anatomic
screening tests, the reference standards range from autopsy
or pathology specimens to another established anatomic
imaging test. Animal studies provide an important source of
direct anatomic correlations, although an inherent degree of
uncertainty exists when translating these studies to human
subjects. Analytic variability studies determine the accuracy
and reproducibility of a method and also generate technical
standards that serve as a basis for vital quality control
standards. Overall, the intertest variability appears to be
lowest for aortic MR, although all techniques have good
reproducibility characteristics. Although older technologies
are all currently trying to add quality control techniques
(vascular ultrasound, echocardiography) and the pitfalls of
lacking quality control are receiving more and more atten-
tion (mammography series, New York Times, June 27 to 28,
2002), quality control must be part of the development and
adoption of any new imaging technology. Finally, biologic
variability of the measurement must be considered. Among
atherosclerosis tests currently available, brachial artery reac-
tivity is affected to the greatest degree by short-term biologic
variability such as menstrual cycle. Biologic variability is also
evident within other anatomic imaging tests. For example, a
moderate degree of variability exists between carotid ultra-
sonography performed in the right and left carotid artery
(71,72). Similar variability is found in the extent of coronary
calcium within different coronary vascular distributions (25).
Cross-sectional intermodality validation studies. Cross-
sectional evaluations of the associations between different
anatomic atherosclerosis assessments are useful to under-
stand the relationships between the results of different tests
performed within specific populations. Such studies provide
important data on the relative prevalence of abnormal test
results within populations, leading to hypotheses regarding
the test performance characteristics of different modalities in
screening settings. Several cross-sectional comparisons of
coronary CT with carotid ultrasonography (73–77) and the
ABI have been reported (73). The Rotterdam Coronary
Calcification Study, a population-based investigation of
subjects over age 55, recently reported the researchers’
experience with EBCT scan, carotid IMT, carotid plaques,
ABI, and aortic calcification measurement in 2,013 subjects
(73). Using coronary calcium scores as the reference mea-
surement, graded associations were found between coronary
calcification and common carotid IMT, carotid plaques, and
aortic calcification. The strongest relationship was between
coronary calcium score and the number of carotid plaques. The
correlation between coronary CT and carotid IMT was
weaker, suggesting that IMT is a less specific marker of
atherosclerosis than is discrete plaque. A nonlinear association
was found between coronary calcification and the ABI, and
abnormal values of the ABI (less than 1.0) were seen in
association with higher coronary calcium scores.
Prospective intermodality validation studies. Technical
validation studies form the foundation for crucial clinical
validation studies evaluating the role of these technologies
in detecting cardiovascular prognosis. The optimal basis for
the comparison of different atherosclerosis imaging modal-
ities is to measure their relative accuracy for the prediction
of future cardiovascular events. Because age, race, and
gender could dramatically affect the test characteristics of a
given modality within a specified population, comparisons
of individual studies using single modalities are insufficient.
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Valid comparisons will require multiple modalities to be
incorporated within a single study, one that optimally includes
a broad range of patient demography, including age. Ulti-
mately, new imaging modalities need to be shown to provide
incremental information about risk beyond what is available
through conventional risk assessment strategies utilizing mea-
sured risk factors (e.g., the Framingham risk score).
IS THERE A CLINICAL HIERARCHY OF
ATHEROSCLEROSIS IMAGING TESTS?
Several potential considerations in the clinical hierarchical
relationship between atherosclerosis imaging tests need to
be weighed. These include the biologic foundation of the
test, age of the population, the clinical availability of the
procedure, its reproducibility, and the extent of prospective
data demonstrating incremental information to the global
risk assessment (Table 1).
Atherosclerosis measurement. Choosing a gold standard
for comparative studies on the measurement of atheroscle-
rosis burden is problematic because atherosclerosis severity
varies within different vascular beds. However, theoretical
considerations can lead to some preliminary hypotheses.
Brachial reactivity is sensitive across a broad range of
atherosclerosis, extending from risk factors that predispose
to atherosclerosis to advanced disease. Its application may
be particularly suited to young individuals who generally
have the most robust vasodilator responses, and thus enable
more accurate separation of normal from abnormal re-
sponses. Carotid ultrasonography can produce categorical
(plaque) or continuous (IMT) measurements. The current
data available on this test support its use principally in
middle-aged and older patients. Studies that have clearly
distinguished IMT from plaque demonstrate that coronary
heart disease (CHD) risk is largely associated with the
presence of nonobstructive or obstructive plaque rather than
IMT (2,78). Increasing common carotid IMT and mean
carotid IMT greater than or equal to 1.0 mm were predic-
tive of future cardiovascular events in women but not in men
following adjustment for risk factors in the ARIC study (4).
Additionally, CCA IMT did not predict risk of MI in the
Rotterdam Study after adjustment for traditional risk factors
(3). Although carotid atherosclerosis is a manifestation of
cerebrovascular disease, the majority of events predicted by
an abnormal carotid ultrasound study are due to coronary
disease, underscoring the systemic nature of atherosclerosis.
Coronary CT to detect coronary calcium reveals advanced
plaques that may be underrepresented in the atherosclerosis
of young individuals and overrepresented in the atheroscle-
rosis of older patients. In contrast, the ABI is abnormal only
in the setting of peripheral arterial disease, which tends to
cluster among patients with more advanced coronary ath-
erosclerosis.
An alternative approach to measurement of atherosclero-
sis burden is to evaluate qualitative characteristics of ath-
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atherosclerosis. Although the utility of such measurements
over simple plaque burden assessments has not been dem-
onstrated, CMR, through its capability of direct plaque
visualization, has the greatest potential to anatomically
distinguish various types of plaques. Soft plaque imaging
with contrast-enhanced coronary CT is a technique under
development for this purpose. Comparative studies includ-
ing emerging biomarker techniques (nuclear techniques) are
also needed.
Detection of cardiovascular risk. Among anatomic
screening tests, IMT, coronary artery calcification (CAC),
and CMR assessments of atherosclerosis extent have weak
to modest correlations with the Framingham risk score.
Except for CMR, for which no data are available, carotid
IMT/plaque, CAC, endothelial dysfunction, and ABI all
predict cardiovascular events, with risk ratios ranging from
two- to eight-fold increased CHD risk for an abnormal test
result. The magnitude of this increased relative risk matches
or exceeds the typical risk ratio for single risk factors (e.g.,
hyperlipidemia) in their ability to predict CHD events.
To date, an independent contribution of anatomic
screening tests over office-based risk factor assessment has
been definitively shown only for abnormal carotid ultra-
sound and ABI (see Task Force 4 report). Although recent
data for CAC are suggestive, considerable controversy exists
on the potential independent role of CAC assessment.
Additional studies, particularly studies comparing multiple
anatomic screening modalities, are needed. Ultimately, the
greatest application of these technologies would be to aid in
the early detection of cardiovascular disease, which would
result in more widespread and effective prevention strate-
gies. None of these imaging technologies have been shown
to make prevention more effective, although their integra-
tion into office-based risk factor assessment is under active
study.
ATHEROSCLEROSIS
MEASUREMENT IN SPECIAL POPULATIONS
Diabetes mellitus. Although all patients with diabetes
mellitus are generally considered to have an increased risk
for cardiovascular events, establishing a gradient of risk
among different patients with diabetes is appealing to refine
the deployment of cardiovascular prevention resources.
Kuller et al. (79) demonstrated in diabetic patients in the
Cardiovascular Health Study that the presence of subclinical
atherosclerosis, determined through a composite measure
including ABI and carotid ultrasonography, confers a
greater risk of cardiovascular events even among individuals
with known diabetes mellitus. Among modalities, BART
may have a specific limitation in diabetes due to augmented
vasodilator responses seen in hyperinsulinemic states leading
to false negative studies, particularly in early diabetes.
Women. There are no data to suggest gender-based limi-
tations to atherosclerosis imaging. However, notable differ-
ences do exist in gender-based distributions of atheroscle-
rosis measurements. Thus, accurate risk assessments will
require the application of gender-specific data on athero-
sclerosis extent and cardiovascular outcomes. Although
IMT values are, in general, lower in women, the relation-
ship between IMT and outcomes in the ARIC study was
stronger in women than in men (4). Coronary calcium
scores on coronary CT are also generally lower for women
than for men; however, recent data indicate greater cardio-
vascular risk for a given calcium score in women (80). The
reasons for this are unknown, but this could be due to
smaller artery size in women (thus, a given absolute calcium
score would represent a greater relative extent of atheroscle-
rosis). The results of BART also require gender adjustment,
as women have a greater vasodilator response than do men.
The relative risk of an abnormal ABI for cardiovascular
events is similar in men and women (81).
Ethnicity. Phenotypic differences in atherosclerosis imag-
ing exist between races, although for many modalities the
extent and implications of these differences is yet to be fully
defined. This has been most clearly demonstrated in coro-
nary CT imaging. After adjustment for cardiovascular risk
factors, blacks have less prevalent and less severe coronary
calcium (82) but a proportionately greater number of coro-
nary events than do whites (83). Although the biologic
foundation for this finding is unclear, these data do indicate
that ethnic group-specific distributions of coronary calcium
scores are needed, and the relationship between these data
and cardiovascular outcomes must be individually defined.
Black individuals are also known to have worse vasodilator
responses on BART, again indicating the need for ethnic-
specific data. Black individuals, in comparison with other
ethnic groups, are twice as likely to have an abnormal ABI
(84,85). In comparison, the reported ethnic differences in
carotid ultrasonography have generally been minor (86,87).
Age. Patient age is an important consideration within
atherosclerosis imaging, although additional cross-sectional
and longitudinal studies with broad age demography are
needed to fully define the limitations of individual imaging
modalities. Theoretically, BART is an optimal technique
for use in young individuals in whom endothelial dysfunc-
tion should precede the development of advanced atheroma.
Similarly, MR, which can detect total aortic atheroma
extent may have a specific advantage in the young. In
contrast, imaging modalities that rely upon the detection of
advanced atheroma (coronary CT and ABI) are more likely
to have a limited role in younger individuals, in whom
advanced atheroma has a relatively low prevalence (leading
to underdetection of cardiovascular risk) and in older
individuals in whom advanced atheroma is too prevalent.
The relationships between age and the outcomes associ-
ated with advanced atheroma may be complex. For example,
the predictive value of vascular calcification for cardiovas-
cular events may diminish with advancing age (17,88). This
may explain the apparent discrepancy in the prognostic
value of coronary CT described in different reported studies,
and it underscores the need for carefully designed longitu-
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dinal studies. Most published data for carotid ultrasonog-
raphy have been from middle-aged and older populations,
and the predictive value for this modality in the young (less
than age 45) has yet to be demonstrated. Finally, the ABI,
which detects more advanced atherosclerosis manifested as
peripheral arterial disease, is particularly well-suited to older
populations.
IMAGING HORIZONS
What future developments within atherosclerosis imaging
can be anticipated? Compared with CMR and BART,
carotid ultrasonography and the ABI are mature technolo-
gies that will provide useful benchmarks for the develop-
ment of new techniques. Although the current scope of
coronary CT is largely limited to coronary calcium detec-
tion, expansion of this technology with contrast enhance-
ment for soft plaque imaging could allow detection of total
coronary plaque burden. Once technically feasible and
validated, the incremental value of this measurement over
coronary calcium assessments must be demonstrated. Use of
CMR has likely the greatest potential for future develop-
ments in the field. Although the spatial and temporal
resolution remains a formidable challenge for coronary
imaging, plaque characterization utilizing nanoparticles or
gadolinium-tagged molecular imaging is currently being
performed in noncoronary vascular beds. In addition, pro-
tocols are being developed to use CMR for detection and
quantification of atherosclerosis in other territories such as
the distal aorta, which may prove useful in the near future.
Development of molecular plaque imaging modalities is in
its infancy but should be a rich source of knowledge on
atherosclerosis bioactivity. Clinical validation of these tech-
nical refinements will be necessary, performed in compari-
son to more established atherosclerosis imaging techniques.
FUTURE DIRECTIONS
1. There is a need for data on the incremental value of new
techniques to standard office-based risk assessment in
order to determine utility.
2. There is a need to move toward broader standardization
of imaging modalities to ensure external validity of the
published data, and to enable cross-study comparisons.
Once standardized, the reproducibility and variability of
a methodology must be defined. This need is particularly
evident for newer modalities. The portability of test
performance characteristics from research centers to
clinical settings must be demonstrated.
3. The currently available atherosclerosis imaging modali-
ties are in different phases of development. Although the
data for ABI and carotid ultrasound are most mature, these
technologies are also most static, with little room for further
development. The effectiveness of more mature modalities
as CHD risk-screening tools cannot be generalized to
newer modalities (e.g., plaque burden testing with CMR
must be independently validated for CHD prognosis).
4. Because atherosclerosis imaging test results can be con-
sidered continuous, improved definition of “positive”
versus “negative” results is needed.
5. There is a need for data on subgroups (e.g., gender and
race) for each modality. Various modalities may perform
differently in detecting CHD prognosis among patient
subgroups.
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Task Force #4—How Do We
Select Patients for Atherosclerosis Imaging?
Peter W. F. Wilson, MD, Co-Chair, Sidney C. Smith, JR, MD, FACC, Co-Chair,
Roger S. Blumenthal, MD, FACC, Gregory L. Burke, MD, Nathan D. Wong, PHD, FACC
The coronary heart disease (CHD) risk assessment should
begin in the office of the physician or other health care
provider. All adults should undergo a standard assessment
to help predict future CHD risk. The American College of
Cardiology (ACC) and the American Heart Association
(AHA) endorse the global risk assessment based on the
Framingham risk prediction model, which includes the
traditional risk factors of age, gender, smoking, blood
pressure, total and high-density lipoprotein (HDL) choles-
terol. Once the patient’s absolute CHD risk is assessed, the
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